Catalent Inc (NYSE:CTLT) shares gained ground Monday, as fourth-quarter financial figures were released.
The company, based in Somerset, New Jersey, reported Q4 revenue of $947.6 million increased 31% as-reported, or 32% in constant currency, compared to the last quarter of fiscal 2019. On an organic basis, constant currency revenue in Q4'20 grew 22% compared to Q4'19.
Fiscal 2020 revenue of $3.1 billion increased 23% as-reported, or 24% in constant currency, from the prior year. On an organic basis, constant currency revenue in FY'20 grew 12% from the prior year.
Net debt leverage was 2.8x as of June 30 vs. 3.8x at March 31, 2020; more than $950 million in cash and cash equivalents on-hand at June 30.
Fourth-quarter 2020 Adjusted Net Income was $154.4 million, or $0.90 per diluted share, compared to Adjusted Net Income of $102.9 million, or $0.70 per diluted share, in the fourth quarter a year ago
Catalent calls itself, "the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products."
Said CEO John Chiminski, "Over the last few years, Catalent has made transformative investments that have shifted our technology portfolio to ever-more innovative and in-demand areas of drug development and manufacturing.
"These investments have positioned us to partner on a wide range of COVID-19 vaccine and treatment candidates, as reflected in more than 50 COVID-19-related program wins, including contracts to manufacture three Operation Warp Speed vaccine candidates."
Shares jumped $2.81, or 3.2%, to $90.46.
Tech Insider
